Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma
Active, not recruiting
Kite, A Gilead Company
Phase 1/Phase 2
2015-01-01
This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2
pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and
Cohort 4, Cohort 5 and Cohort 6).
The primary objectives of this study are:
- Phase 1 Study: Evaluate the safety of axicabtagene ciloleucel regimens
- Phase 2 Pivotal Study; Evaluate the efficacy of axicabtagene ciloleucel
- Phase 2 Safety Management Study: Assess the impact of prophylactic regimens or earlier
interventions on the rate and severity of cytokine release syndrome (CRS) and neurologic
toxicities
Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Active, not recruiting
Kite, A Gilead Company
Phase 2
2015-11-09
The primary objective of the study is to evaluate the efficacy of brexucabtagene autoleucel
(KTE-X19) in participants with relapsed/refractory mantle cell lymphoma (MCL)
Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Active, not recruiting
Genentech, Inc.
Phase 1/Phase 2
2016-09-29
The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab
combination regimens.
The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as
measured by complete response rate in participants with refractory diffuse large B-cell
lymphoma (DLBCL).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
